Date: November 16, 2026
Regulatory Disclosure Summary
Wanbury Limited has submitted a regulatory filing pursuant to Regulation 30 of SEBI LODR regarding the outcome of a US FDA inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility.
Inspection Details
- Facility Location: Tanuku, Andhra Pradesh
- Inspecting Authority: United States Food and Drug Administration (US FDA)
- Inspection Period: July 13, 2026 to July 17, 2026
- Initial Intimation Date: July 22, 2026
- Classification Received: Official Action Indicated (OAI)
Business Impact Assessment
According to the company's current assessment, the OAI classification:
- Will not have any impact on business continuity
- Will not affect customer supplies of existing products from this facility
Company Commitment
Wanbury Limited states that it:
- Remains committed to working closely with the US FDA
- Will maintain the highest standards of quality, regulatory compliance and manufacturing practices across all facilities
- Will enhance its compliance on an ongoing basis
Filing Details
- Filed Through: Jitendra J. Gandhi, Company Secretary
- Digital Signature Date: November 16, 2026 at 13:49:16 IST
- Regulatory Reference: SEBI LODR Regulation 30